Proteon Therapeutics Grabs $45M in Series D Financing
May 19, 2014
Proteon Therapeutics, a developer of pharmaceuticals to address the medical needs of patients with kidney and vascular diseases, announced $45 million of Series D equity financing, including a $25-million tranche to fully fund the first Phase 3 clinical study of its lead product. PRT-201 is a recombinant human elastase in development to prolong the patency and reduce the failure of hemodialysis vascular access in patients with chronic kidney disease. The Phase 3 study will evaluate PRT-201 in patients undergoing surgical placement of an arteriovenous fistula, the optimal form of vascular access for hemodialysis patients.